HK Stock Market Move | INSILICO (03696) surged over 6% breaking through the ceiling. NLRP3 inhibitor ISM8969 received FDA clinical trial approval.

INSILICO (03696) rose by more than 6%, reaching a high of 62.9 Hong Kong dollars, a new record high for the company. As of the time of writing, it has increased by 6.11% to 62.5 Hong Kong dollars, with a trading volume of 26.3799 million Hong Kong dollars. On the news front, INSILICO announced today that its oral NLRP3 inhibitor ISM8969 for the treatment of inflammation and neurodegenerative diseases has received approval for Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson's disease. The upcoming Phase I clinical study aims to evaluate the safety, tolerability, pharmacokinetics of ISM8969 in healthy subjects, and to find the clinically recommended optimal dose for further research. It is worth mentioning that in order to accelerate the global development of ISM8969, INSILICO has reached a joint development agreement with Hengtai Bio. Both parties hold 50% of the global rights to the project, and INSILICO has the right to receive a maximum of over 500 million Hong Kong dollars in upfront and milestone payments. In addition, INSILICO recently released the large language model training framework, Science MMAI Gym, with the aim of transforming the LLM with causal reasoning capabilities into a high-performance engine capable of handling drug discovery and development tasks in the real world. After training, the originally high failure rate LLM in the professional task field can achieve up to 10 times performance improvement in key drug discovery benchmark tests. This release will further advance the Pharmaceutical Superintelligence (PSI) vision.